T1	Participants 638 746	186 patients received either indomethacin 3 times daily, or rofecoxib twice, and 1 placebo, daily for 7 days
T2	Participants 861 970	12 of the 186 patients included discontinued their medication before the end of the trial due to side effects
T3	Participants 972 1028	The remaining 174 patients were included in the analysis
T4	Participants 1030 1187	In the indomethacin group (n = 89), 77 patients (87%) showed no HO, 9 showed HO of grade 1 and 3 showed HO of grade 2 according to the Brooker classification
T5	Participants 1189 1302	In the rofecoxib group (n = 85) 73 patients (86%) showed no ossification, 9 showed grade 1, and 3 showed grade 2.
